The Antiepileptic Drug Development Program: an example of government-industry collaboration.
By collaborating with the pharmaceutical industry in key areas of drug development, the ADD Program of the Epilepsy Branch, National Institute of Neurological and Communicative Disorders and Stroke, has responded to the need for more effective and less toxic antiepileptic drugs than those currently available. The program screens large numbers of compounds for anticonvulsant activity, conducts toxicology studies, and sponsors clinical trials of promising new drugs for the treatment of epilepsy. This collaboration with the pharmaceutical industry is providing a valuable model for a shared drug development program.
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry / Q000191:economics; D004363:Drug Utilization; D006076:Government; D009316:National Institutes of Health (U.S.); D009965:Orphan Drug Production / Q000191:economics; D014481:United States
D000927:Anticonvulsants